Related references
Note: Only part of the references are listed.Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients
Akihito Kawazoe et al.
GASTRIC CANCER (2017)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
Harold J. Burstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial.
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer
B. W. Kang et al.
ANNALS OF ONCOLOGY (2016)
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma
Hans A. Schloesser et al.
ONCOIMMUNOLOGY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
Niall C. Tebbutt et al.
BRITISH JOURNAL OF CANCER (2016)
Distinct Subtypes of Gastric Cancer Defined by Molecular Characterization Include Novel Mutational Signatures with Prognostic Capability
Xiangchun Li et al.
CANCER RESEARCH (2016)
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
Leandro M. Colli et al.
CANCER RESEARCH (2016)
Microsatellite Instability as a Biomarker for PD-1 Blockade
Jonathan C. Dudley et al.
CLINICAL CANCER RESEARCH (2016)
Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma
Eirini Pectasides
CLINICAL THERAPEUTICS (2016)
Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?
Marie de Charette et al.
EUROPEAN JOURNAL OF CANCER (2016)
The emerging role of immunotherapy in gastric and esophageal adenocarcinoma
Bruno Bockorny et al.
FUTURE ONCOLOGY (2016)
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma
Min Dong et al.
HUMAN PATHOLOGY (2016)
Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with advanced gastric or gastroesophageal junction cancer.
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Manish A. Shah et al.
ONCOLOGIST (2016)
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints
Maria Alsina et al.
TARGETED ONCOLOGY (2016)
Immunological battlefield in gastric cancer and role of immunotherapies
Minyu Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials
Seongseok Yun et al.
CANCER MEDICINE (2016)
Novel targets in the treatment of advanced gastric cancer: a perspective review
Elisa Fontana et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Cell Type-Specific Regulation of Immunological Synapse Dynamics by B7 Ligand Recognition
Joanna Brzostek et al.
FRONTIERS IN IMMUNOLOGY (2016)
Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?
Giuseppe Aprile et al.
TRANSLATIONAL CANCER RESEARCH (2016)
Immunotherapy for Gastroesophageal Cancer
Emily F. Goode et al.
JOURNAL OF CLINICAL MEDICINE (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
Giuseppe Aprile et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and Outcomes
Sun Young Kim et al.
GASTROENTEROLOGY (2015)
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu et al.
NATURE MEDICINE (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics
D. Massi et al.
ANNALS OF ONCOLOGY (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comprehensive molecular characterization of gastric adenocarcinoma
Adam J. Bass et al.
NATURE (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors
Ronggui Guan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
Tom Waddell et al.
LANCET ONCOLOGY (2013)
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
Florian Lordick et al.
LANCET ONCOLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
Antoni Ribas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact
Wolf-Herman Fridman et al.
CANCER MICROENVIRONMENT (2013)
Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Monica Bernal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Modulation of Immunity by Antiangiogenic Molecules in Cancer
Magali Terme et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Decreased Expression of the ARID1A Gene Is Associated with Poor Prognosis in Primary Gastric Cancer
Dan-dan Wang et al.
PLOS ONE (2012)
The immune microenvironment as a guide for cancer therapies
Wolf H. Fridman
ONCOIMMUNOLOGY (2012)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
Christy Ralph et al.
CLINICAL CANCER RESEARCH (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Meta-analysis Shows That Prevalence of Epstein-Barr Virus-Positive Gastric Cancer Differs Based on Sex and Anatomic Location
Gwen Murphy et al.
GASTROENTEROLOGY (2009)
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers
Yvette Schwitalle et al.
GASTROENTEROLOGY (2008)
Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases
A Buckowitz et al.
BRITISH JOURNAL OF CANCER (2005)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
